ETS2 and prostate carcinoma: The finding in this study could provide novel therapeutic targets and diagnostics for future ESCC therapy, as direct inhibition of Ets2 transcription by triplex forming oligonucleotides resulted in growth inhibition and induction of apoptosis in human prostate cancer cells [28].